{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:42:08Z","timestamp":1778190128766,"version":"3.51.4"},"reference-count":58,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has been approved for CTD-ILD treatment. The aim of this study was to assess the effectiveness and safety of nintedanib in CTD-ILD patients in a real-world data setting. A single-center, retrospective, and descriptive analysis of CTD-ILD patients treated with nintedanib from June 2019 to November 2022 was performed. The assessment of nintedanib treatment\u2019s efficacy was judged solely on the evolution of pulmonary function tests (PFTs), which were evaluated before and after treatment. Twenty-one patients (67% females, median age 64 years (IQR = 9) with CTD-ILD (systemic sclerosis n = 9, rheumatoid arthritis n = 5, dermatomyositis n = 4, juvenile rheumatoid arthritis n = 1, undifferentiated CTD n = 1, interstitial pneumonia with autoimmune features n = 1), 18 of whom were on concomitant immunosuppressives, had a median follow-up period of 10 months (IQR = 5). PFTs before and after treatment did not significantly differ. The mean FVC% difference was +0.9 (sd = 7.6) and the mean DLco% difference was +3.4 (sd = 12.6), suggesting numerical improvement of PFTs. The average percentage change was \u22120.3% and +7.6% for FVC% and DLco%, respectively, indicating stabilization of lung function. Our real-world data across a broad spectrum of CTD-ILD suggest that nintedanib could be beneficial in combination with immunosuppressives in slowing the rate of lung function decline.<\/jats:p>","DOI":"10.3390\/diagnostics13071221","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T02:34:54Z","timestamp":1679625294000},"page":"1221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience"],"prefix":"10.3390","volume":"13","author":[{"given":"Maria","family":"Boutel","sequence":"first","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7366-2038","authenticated-orcid":false,"given":"Afroditi","family":"Boutou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, 57010 Pylaia-Chortiatis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Pitsiou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Failure, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, 57010 Pylaia-Chortiatis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Garyfallos","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","first-page":"343","article-title":"Pulmonary Fibrosis, Part I: Epidemiology, Pathogenesis, and Diagnosis","volume":"11","author":"Meyer","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"180074","DOI":"10.1183\/16000617.0074-2018","article-title":"Pharmacological Management of Progressive-Fibrosing Interstitial Lung Diseases: A Review of the Current Evidence","volume":"27","author":"Richeldi","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","first-page":"2","article-title":"Investigation of Lung Involvement in Connective Tissue Disorders","volume":"90","author":"Papiris","year":"2015","journal-title":"Respir. Int. Rev. Thorac. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","article-title":"Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment","volume":"198","author":"Jeganathan","year":"2020","journal-title":"Lung"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2665-9913(21)00250-2","article-title":"Current Issues in Rheumatoid Arthritis-Associated Interstitial Lung Disease","volume":"3","author":"Kelly","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cassone, G., Manfredi, A., Vacchi, C., Luppi, F., Coppi, F., Salvarani, C., and Sebastiani, M. (2020). Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041082"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.31138\/mjr.29.4.236","article-title":"Rheumatoid Arthritis-Associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study","volume":"29","author":"Karageorgas","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic Sclerosis\u2013Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration\u2013Approved Therapies in Clinical Practice","volume":"74","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200340","DOI":"10.1183\/16000617.0340-2020","article-title":"Natural Variability in the Disease Course of SSc-ILD: Implications for Treatment","volume":"30","author":"Vonk","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13665-022-00290-w","article-title":"Management of Connective Tissue Disease\u2013Related Interstitial Lung Disease","volume":"11","author":"Ahmed","year":"2022","journal-title":"Curr. Pulmonol. Rep."},{"key":"ref_13","first-page":"165","article-title":"The Use of Ultrasound for Assessing Interstitial Lung Involvement in Connective Tissue Diseases","volume":"36","author":"Ferro","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective Tissue Disease-Associated Interstitial Lung Diseases (CTD-ILD)\u2014Report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 Guide for the Diagnosis and Treatment of Interstitial Lung Disease Associated with Connective Tissue Disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MCP.0000000000000600","article-title":"New Trajectories in the Treatment of Interstitial Lung Disease","volume":"25","author":"Morisset","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.31138\/mjr.31.3.330","article-title":"Interstitial Pneumonia with Autoimmune Features (IPAF): A Single-Centre, Prospective Study","volume":"31","author":"Karampeli","year":"2020","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pulmoe.2019.08.004","article-title":"A Role of Antifibrotics in the Treatment of Scleroderma-ILD?","volume":"26","author":"Antoniou","year":"2020","journal-title":"Pulmonology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Randomised Controlled, Double-Blind, Parallel Group Trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of Rituximab on the Progression of Rheumatoid Arthritis-Related Interstitial Lung Disease: 10 Years\u2019 Experience at a Single Centre","volume":"56","author":"Kabia","year":"2017","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus Intravenous Cyclophosphamide in Patients with Connective Tissue Disease-Associated Interstitial Lung Disease in the UK (RECITAL): A Double-Blind, Double-Dummy, Randomised, Controlled, Phase 2b Trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Literature Review","volume":"20","author":"Blanco","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"925776","DOI":"10.3389\/fimmu.2022.925776","article-title":"Case Report: A Successful Second Autologous Hematopoietic Stem Cell Transplantation in Refractory Systemic Sclerosis, with Positive Effect on Skin Involvement, Pulmonary Function and Microcirculation","volume":"13","author":"Haverkort","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102245","DOI":"10.1016\/j.coph.2022.102245","article-title":"Treatment Approach to Connective Tissue Disease-Associated Interstitial Lung Disease","volume":"65","author":"Wilson","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: A Review in Fibrotic Interstitial Lung Diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD Trial: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13075-021-02710-9","article-title":"Impact of Lung Function Decline on Time to Hospitalisation Events in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): A Joint Model Analysis","volume":"24","author":"Kreuter","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS Technical Standard on Interpretive Strategies for Routine Lung Function Tests","volume":"60","author":"Stanojevic","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"v27","DOI":"10.1093\/rheumatology\/kex203","article-title":"Interstitial Lung Disease Points to Consider for Clinical Trials in Systemic Sclerosis","volume":"56","author":"Khanna","year":"2017","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and Minimal Clinically Important Differences of Forced Vital Capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11739-016-1573-9","article-title":"Utility of FVC\/DLCO Ratio to Stratify the Risk of Mortality in Unselected Subjects with Pulmonary Hypertension","volume":"12","author":"Donato","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_39","first-page":"2020","article-title":"Antifibrotic Drugs in Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD): From Mechanistic Insights to Therapeutic Applications","volume":"10","author":"Erre","year":"2021","journal-title":"Drugs Context"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pulmoe.2020.01.004","article-title":"Connective Tissue Disease-Associated Interstitial Lung Disease","volume":"28","author":"Oliveira","year":"2020","journal-title":"Pulmonology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in Patients with Autoimmune Disease\u2013Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of INBUILD Trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","first-page":"161","article-title":"Antifibrotics in Interstitial Lung Disease Related to Connective Tissue Diseases\u2014A Paradigm Shift in Treatment and Outcome","volume":"44","author":"Duarte","year":"2019","journal-title":"Acta Reumatol. Port."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cameli, P., Alonzi, V., d\u2019Alessandro, M., Bergantini, L., Pordon, E., Guerrieri, M., Refini, R.M., Sestini, P., and Bargagli, E. (2022). The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081973"},{"key":"ref_44","first-page":"1","article-title":"Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan","volume":"2023","author":"Ogura","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.31138\/mjr.30.3.147","article-title":"Lung Disease in Rheumatic Disorders","volume":"30","author":"Kelly","year":"2019","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in Patients with Systemic Sclerosis\u2013Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0029-1244054","article-title":"Das Anti-Jo-1-Syndrom\u2014Eine Sonderform Der Myositis Mit Interstitieller Lungenerkrankung","volume":"64","author":"Gillissen","year":"2010","journal-title":"Pneumologie"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study","volume":"8","author":"Liang","year":"2021","journal-title":"Front. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2017.00123","article-title":"Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management","volume":"4","author":"Oldham","year":"2017","journal-title":"Front. Med."},{"key":"ref_50","first-page":"571","article-title":"Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies","volume":"96","author":"Wang","year":"2018","journal-title":"Respir. Int. Rev. Thorac. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.31138\/mjr.29.3.140","article-title":"Interstitial Lung Disease in Systemic Sclerosis: Insights into Pathogenesis and Evolving Therapies","volume":"29","author":"Ahmed","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.31138\/mjr.30.1.33","article-title":"Treatment of Systemic Sclerosis Associated Fibrotic Manifestations: Current Options and Future Directions","volume":"30","author":"Daoussis","year":"2019","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Short-Term Outcomes and Predictors of Progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e002477","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and Safety of Tocilizumab in Patients with Systemic Sclerosis: A Propensity Score Matched Controlled Observational Study of the EUSTAR Cohort","volume":"8","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and Immunomodulatory Therapies in Progressive Fibrosing Interstitial Lung Diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12931-022-01974-2","article-title":"Safety and Tolerability of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the Randomized Controlled INBUILD Trial","volume":"23","author":"Cottin","year":"2022","journal-title":"Respir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","article-title":"Tolerability and Safety of Nintedanib in Elderly Patients with Idiopathic Pulmonary Fibrosis","volume":"59","author":"Uchida","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Komatsu, M., Yamamoto, H., Ichiyama, T., Kawakami, S., Uehara, T., Yoshikawa, Y., Kitaguchi, Y., Ushiki, A., Yasuo, M., and Hanaoka, M. (2022). Tolerability of Nintedanib in the Elderly with Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262795"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/7\/1221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:44Z","timestamp":1760122904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/7\/1221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["diagnostics13071221"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13071221","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}